
Novartis has presented new Phase 2 data for its humanised anti-P-selectin monoclonal antibody crizanlizumab in the treatment of sickle cell …
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ

